Skip to main content
Fig. 3 | Journal of Experimental & Clinical Cancer Research

Fig. 3

From: Dual inhibition of CDK12 and CDK13 uncovers actionable vulnerabilities in patient-derived ovarian cancer organoids

Fig. 3

CDK12/13 inhibition impairs viability of HGSOC PDOs and synergizes with Olaparib and Paclitaxel. a, b Cytotoxic effects of THZ531 (a), Olaparib and Paclitaxel (b) on the indicated PDO lines. Cells were exposed to various concentrations of the drugs for 5 days and viability was evaluated by Cell Titer Glo 3D assay. Half-maximal inhibitory concentration (IC50) values were determined from fitting curves using GraphPad Prism 9.0. All results represent the mean ± SEM of technical triplicates. c,d, Synergic effects of THZ531 and Olaparib (c) or Paclitaxel (d) on viability of the indicated PDO lines. Organoids were exposed for 5 days to combined treatments with suboptimal doses of THZ531 (30 nM and 50 nM), Olaparib (1 and 10 µM) and Paclitaxel (2 and 20 nM) (*P < 0.05, **P < 0.01, ***P < 0.001). CI values < 1, which suggest synergism, was calculated for drug combinations relative to the individual drugs and are indicated above the graphs. All results are expressed as the mean ± SEM derived from technical triplicates

Back to article page